July 23, 2019 – Banner Life Sciences Announces First Subject Enrolled in Randomized, Double-Blind Head-to-Head Study of Bafiertam and Tecfidera for Comparative Assessment of GI Tolerability
View full release as a pdf here:
January 02, 2019 – Banner Receives FDA Tentative Approval for BAFIERTAM for the Treatment of Relapsing Forms of Multiple Sclerosis
View full release as a pdf here: